FLJ37201: A Pseudogene with Potential as A Drug Target Or Biomarker

Target Name: FLJ37201

NCBI ID: G283011

FLJ37201

Other Name(s): tigger transposable element derived 2 pseudogene | Tigger transposable element derived 2 pseudogene

FLJ37201: A Pseudogene with Potential as A Drug Target Or Biomarker

FLJ37201 is a pseudogene that is derived from a transposable element in the human genome. It is a non-coding RNA molecule that has been shown to play a critical role in the regulation of gene expression. FLJ37201 is also known as a potential drug target or biomarker, and a number of studies have investigated its potential utility in the development of new treatments for various diseases.

History of Discovery

The discovery of FLJ37201 was made by a team of researchers at the University of California, San Diego. The team identified the transposable element in the human genome that was responsible for the production of FLJ37201. They then used a variety of techniques to show that FLJ37201 was transcribed from this element and that it had the potential to be a functional RNA molecule.

Function and Regulation

FLJ37201 is a non-coding RNA molecule that is expressed in almost all human tissues. It has been shown to play a critical role in the regulation of gene expression by mechanisms such as RNA-protein interactions and post-transcriptional modification. FLJ37201 is able to interact with a variety of protein partners, including known regulators of gene expression such as RNA-binding proteins (RBPs) and RNA interference (RNAi) molecules.

FLJ37201 is also involved in the regulation of cellular processes such as cell growth, apoptosis, and cell-cell signaling. It has been shown to play a role in the regulation of cell cycle progression, and it has been shown to interact with molecules involved in the G1/S transition, G0/G1 transition, and the G2/M transition.

Drug Target Potential

FLJ37201 has been shown to have a number of potential drug targets. For example, it has been shown to play a role in the regulation of cell adhesion, and it has been shown to interact with molecules involved in cell-cell adhesion. This suggests that FLJ37201 may be a useful target for drugs that are designed to modulate cell-cell adhesion.

FLJ37201 has also been shown to play a role in the regulation of cell survival. It has been shown to interact with molecules involved in cell cycle progression and apoptosis, and it has been shown to be involved in the regulation of cell survival. This suggests that FLJ37201 may be a useful target for drugs that are designed to inhibit cell death.

Competitive Analysis

There are currently a number of drugs that are being developed as potential treatments for various diseases, and some of these drugs may be effective because they are able to modulate the activity of FLJ37201. For example, some drugs that are being developed to treat cancer may be able to inhibit the activity of FLJ37201 and thereby inhibit its ability to regulate gene expression.

Conclusion

FLJ37201 is a pseudogene that is derived from a transposable element in the human genome. It is a non-coding RNA molecule that has been shown to play a critical role in the regulation of gene expression and the regulation of cellular processes. FLJ37201 has potential as a drug target or biomarker, and a number of studies have shown that it is involved in the regulation of cell adhesion, cell survival and the cell cycle progression. Further studies are needed to fully understand the potential utility of FLJ37201 as a drug target or biomarker .

Protein Name: Tigger Transposable Element Derived 2 Pseudogene

The "FLJ37201 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about FLJ37201 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets